Drug-drug interactions: is there an optimal way to study them?
作者信息
Lewis L D
出版信息
Br J Clin Pharmacol. 2010 Dec;70(6):781-3. doi: 10.1111/j.1365-2125.2010.03829.x.
Abstract
摘要
相似文献
1
Drug-drug interactions: is there an optimal way to study them?药物相互作用：是否存在研究它们的最佳方法？
Br J Clin Pharmacol. 2010 Dec;70(6):781-3. doi: 10.1111/j.1365-2125.2010.03829.x.
2
[Characteristics and design of the studies evaluating pharmacological interactions].[评估药物相互作用的研究的特征与设计]
Med Clin (Barc). 2013 Jul 21;141(2):82-6. doi: 10.1016/j.medcli.2013.04.006. Epub 2013 May 22.
3
Review of the application of response surface methodology in the combination therapy of cancer.响应面法在癌症联合治疗中的应用综述
Cancer Treat Rep. 1986 Jan;70(1):133-40.
4
Overview of experimental approaches for study of drug metabolism and drug-drug interactions.药物代谢与药物相互作用研究的实验方法概述
Adv Pharmacol. 1997;43:255-77. doi: 10.1016/s1054-3589(08)60210-0.
5
6
Assessment of drug metabolites.药物代谢物的评估。
Drug Metab Pharmacokinet. 2011;26(2):121-2. doi: 10.2133/dmpk.dmpk-11-pf-902.
7
Pregnane X receptor: predicting and preventing drug interactions.孕烷X受体：预测和预防药物相互作用。
Thromb Res. 2005;117(1-2):133-6; discussion 145-51. doi: 10.1016/j.thromres.2005.07.001. Epub 2005 Aug 8.
8
Biostatistics in nonclinical and preclinical drug development.
Biom J. 2005 Jun;47(3):282-5. doi: 10.1002/bimj.200510128.
9
The impact of preclinical irreproducibility on drug development.临床前不可重复性对药物研发的影响。
Clin Pharmacol Ther. 2015 Jan;97(1):16-8. doi: 10.1002/cpt.9. Epub 2014 Dec 2.
10
Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.药物研发过程中抑制性药物相互作用的评估：必须考虑基因多态性。
Clin Pharmacol Ther. 2005 Jul;78(1):1-6. doi: 10.1016/j.clpt.2005.04.006.
引用本文的文献
1
Evaluation of drug-drug interaction potentials between JP-1366 and celecoxib using physiologically based pharmacokinetic modeling.使用基于生理的药代动力学模型评估 JP-1366 与塞来昔布之间的药物相互作用潜力。
Transl Clin Pharmacol. 2025 Jun;33(2):90-99. doi: 10.12793/tcp.2025.33.e10. Epub 2025 Jun 27.
2
Regulation of chronic neuroinflammation through dietary herbal products.通过食用草药产品调节慢性神经炎症。
Front Nutr. 2025 Apr 9;12:1487786. doi: 10.3389/fnut.2025.1487786. eCollection 2025.
3
A computational approach to predict multi-pathway drug-drug interactions: A case study of irinotecan, a colon cancer medication.一种预测多途径药物相互作用的计算方法：以结肠癌药物伊立替康为例。
Saudi Pharm J. 2020 Dec;28(12):1507-1513. doi: 10.1016/j.jsps.2020.09.017. Epub 2020 Sep 29.
4
Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape.阿尔茨海默病的健康结果优先排序：理解伦理景观。
J Alzheimers Dis. 2020;77(1):339-353. doi: 10.3233/JAD-191300.
5
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.一项评估仑伐替尼对晚期实体瘤患者中 CYP3A4 底物咪达唑仑药代动力学影响的开放标签、Ⅰ期研究。
Eur J Drug Metab Pharmacokinet. 2020 Jun;45(3):373-383. doi: 10.1007/s13318-020-00607-7.
6
Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing.基于能量模型布局的药物-药物相互作用网络聚类：社区分析和药物再利用。
Sci Rep. 2016 Sep 7;6:32745. doi: 10.1038/srep32745.
7
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.I期联合试验设计：美国国立癌症研究所研究性药物指导委员会临床试验设计工作组的建议
Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521.
8
Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.药物-药物相互作用导致的不良反应中细胞色素 P450（CYP450）的重要性：法国的药物警戒研究。
Eur J Clin Pharmacol. 2013 Apr;69(4):885-8. doi: 10.1007/s00228-012-1394-3. Epub 2012 Sep 21.
9
The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.药物-药物相互作用作为药物不良反应原因的重要性：法国对 5-羟色胺再摄取抑制剂的药物警戒研究。
Eur J Clin Pharmacol. 2012 May;68(5):767-75. doi: 10.1007/s00228-011-1156-7. Epub 2011 Nov 25.
10
Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.强 CYP2D6 和 3A4 抑制剂帕罗西汀和酮康唑对坦索罗辛药代动力学和心血管安全性的影响。
Br J Clin Pharmacol. 2011 Aug;72(2):247-56. doi: 10.1111/j.1365-2125.2011.03988.x.
本文引用的文献
1
Erlotinib and pantoprazole: a relevant interaction or not?厄洛替尼和泮托拉唑：存在相关相互作用？还是没有？
Br J Clin Pharmacol. 2010 Dec;70(6):908-11. doi: 10.1111/j.1365-2125.2010.03748.x.
2
The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.NK₁ 受体拮抗剂阿瑞匹坦不会改变多发性骨髓瘤患者大剂量马法兰化疗的药代动力学。
Br J Clin Pharmacol. 2010 Dec;70(6):903-7. doi: 10.1111/j.1365-2125.2010.03792.x.
3
Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients.奥司他韦治疗对抗凝的影响：华法林抗凝患者的交叉研究。
Br J Clin Pharmacol. 2010 Dec;70(6):834-43. doi: 10.1111/j.1365-2125.2010.03780.x.
4
Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.当达塞曲匹与依泽替米贝合用时，缺乏具有临床意义的药物相互作用。
Br J Clin Pharmacol. 2010 Dec;70(6):825-33. doi: 10.1111/j.1365-2125.2010.03763.x.
5
Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review.右美沙芬、氯苯那敏和 5-羟色胺毒性：病例报告和系统文献回顾。
Br J Clin Pharmacol. 2010 Dec;70(6):794-8. doi: 10.1111/j.1365-2125.2010.03747.x.
6
Clopidogrel with or without omeprazole in coronary artery disease.氯吡格雷联合或不联合奥美拉唑用于冠心病。
N Engl J Med. 2010 Nov 11;363(20):1909-17. doi: 10.1056/NEJMoa1007964. Epub 2010 Oct 6.
7
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.质子泵抑制剂对氯吡格雷治疗患者临床结局的影响：系统评价和荟萃分析。
J Thromb Haemost. 2010 Dec;8(12):2624-41. doi: 10.1111/j.1538-7836.2010.04049.x.
8
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.药物相互作用对氯吡格雷体外生物转化和抗血小板作用的影响。
Br J Pharmacol. 2010 Sep;161(2):393-404. doi: 10.1111/j.1476-5381.2010.00881.x.
9
Drug interaction studies: study design, data analysis, and implications for dosing and labeling.药物相互作用研究：研究设计、数据分析以及对给药和标签的影响。
Clin Pharmacol Ther. 2007 Feb;81(2):298-304. doi: 10.1038/sj.clpt.6100054.
10
Classifying drug interactions.药物相互作用的分类
Br J Clin Pharmacol. 2004 Oct;58(4):343-4. doi: 10.1111/j.1365-2125.2004.02244.x.
Zotero 插件